Drug or technology
6 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 8, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
Phase 2 interventional trial with planned safety and efficacy endpoints in EGFR-mutant NSCLC; no results reported in this registry record.
AUG 20, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a Phase 3 trial registry record with no results posted; the study is active but not recruiting, and outcomes have not yet been reported in this source.
AUG 20, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a Phase 3 RCT registry record with no posted results; the study is active but not recruiting, and outcomes remain unreported in this source.
JUL 31, 2026 · PHASE 1/2 TRIAL
ClinicalTrials.gov
This is an active clinical trial registry record with no posted results; it describes the planned Phase 1/2 study design and endpoints only.
JUL 31, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
This is an active interventional Phase 2 trial registry record with no results reported; it describes a planned study of premedication strategies to reduce amivantamab infusion reactions in non-small-cell lung cancer.
JUL 31, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
This is a recruiting Phase 2 trial registration with no results posted; outcomes remain unknown and cannot be assessed.